Dr. Michael Boyle with CFTR image in background


Share This Page    

Milestones in CF research at Johns Hopkins are a mile long. Among other achievements, its basic scientists and clinical investigators have helped define the pathology of the disease, identify the CF gene, and develop genetic therapies and antibiotics for CF. Today, they continue to study the pathobiology of CF and test new therapies, including:  CFTR modulator drugs that improve the function of the defective CFTR chloride channel, AAV gene therapy, drugs that stimulate alternative chloride channels, and mucus-thinning drugs designed to reduce infections and improve lung function. And as researchers for the Johns Hopkins Cystic Fibrosis Center, one of centers around the country that make up the Cystic Fibrosis Foundation’s Therapeutic Development Network, they focus on expediting the early phases of clinical trials to get new, more-effective CF drugs and treatments to patients. In this section of the website we’ll tell you about our recent and ongoing research, how to enroll in clinical trials, and the latest news in the quest to find a cure for CF.